



Content highlights

Release date

November 2024

Updated throughout the year to reflect Clarivate's expert analysis of the latest major-market events

Geography

United States, EU5, Japan

Primary research

19 country-specific interviews with thought-leading endocrinologists

Supported by survey data collected for this and other Clarivate research

Epidemiology

Prevalence of obesity and drug-treatable overweight by country, including diagnosed and drug-treated populations

Forecast

10-year, annualized, drug-level sales and patient share of key obesity therapies through 2033, segmented by brands / generics epidemiological subpopulations

Drug treatments

Coverage of key current and emerging therapies

Obesity / Overweight

Spotlight on Disease Landscape & Forecast

Market outlook

Obesity is a significant and growing public health concern in the major markets. The body of evidence highlighting the medical and economic impact of obesity on society is steadily increasing. Despite the disease's prevalence, approved drugs are scarce compared with other chronic metabolic diseases, especially in Europe and Japan. However, the development pipeline is strengthening with novel agents that promise to address some of the limitations of current treatments. The market opportunity for antiobesity drugs that elicit greater and sustained weight loss and are safe, well tolerated, and affordable is substantial. However, given the prevalence of the disease, even if such agents are developed and approved, payers will likely need to restrict their access to limit the strain on finite healthcare budgets.

Questions answered

- Which metabolic and central pathways have high potential as drug targets?
- What is the prevalence of obesity in the major pharmaceutical markets under study?
- How is obesity currently treated? What are experts' opinions of Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide) for obese / overweight patients?
- What is the commercial potential of emerging therapies? How do leaders in the field of obesity management rate these drug candidates?
- How will the obesity therapy market evolve over the next 10 years?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Learn more about Clarivate's full suite of obesity / overweight solutions:

healthcare.support@clarivate.com | clarivate.com